Neoadjuvant chemotherapy in patients with locally advanced breast cancer

Dodiya, Hardik; Brahmbhatt, Alay P; Khatri, Priyanka; Kaushal, Ashish; Vijay, DG

doi:10.4103/0973-1482.146056

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dondiya et al study showed complete pathological response in 17%, partial response in 61% and stable disease in 21% of patients. 12 Earlier studies conducted in India reported, 18.9% complete PCR response for docetaxel chemotherapy and 13.2% showed complete pathological response for AC chemotherapy. 13 In present study the mean tumour size was 7.29±2.19 cm, 4.09±2.6 cm respectively before and after NACT, showed significant reduction in tumour size with NACT (p<0.0001).…”

Section: Resultsmentioning

confidence: 96%

Evaluation of neo adjuvant chemotherapy response in patients with locally advanced breast cancer

et al. 2020

View full text Add to dashboard Cite

Background: Carcinoma of the breast from the very beginning has been a feared disease. Advanced disease is treated by neoadjuvant chemotherapy (NACT). With this, a study was conducted to evaluate the pathologic response to NACT in locally advanced breast cancer.Methods: Study was conducted in GSL Medical College, approved by institutional ethics committee, females aged >18 years with locally advanced breast cancer were included in the study. Female <18 years and breast cancer male were not considered. The dimensions are marked and size of the lump compared before and after NACT. Chi-square test was used to find out the significance of study parameters; p<0.05 was considered statistically significant.Results: Total 110 patients were included in the study, mean age was 50.63±10.76 years and 53% were in pre menopausal women. When pathological response was considered, 12.7% had complete response, 66.4% had partial response and 20.9% had no response to NACT; statistically there was significant difference between pre and post treatment tumor sizes (p<0.05).Conclusions: Most of the individuals belonged to premenopausal group. Tumour size showed significant decrease after NACT. The overall response rate (complete and partial) after NACT was significant in our study group.

show abstract

Section: Resultsmentioning

confidence: 96%

Evaluation of neo adjuvant chemotherapy response in patients with locally advanced breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It has been shown in the adjuvant setting than replacing the last 2 FEC 100 cycles of 6 FEC100 regimen by 4 Taxol does not lead to a discernable DFS or OS advantage [25]. However, in the neoadjuvant setting, anthracycline and taxane-based chemotherapy would give a higher rate of pCR over the anthracycline-based chemotherapy [26]. In our study, almost the same proportion of patients received 3 FEC 100 and 3 taxanes in each group, but the midcourse switch to taxanes is a limit.…”

Section: Discussionmentioning

confidence: 99%

Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer

Grapin

Coutant

Riedinger

et al. 2019

European Journal of Radiology

View full text Add to dashboard Cite

“…This is considered a window of opportunity for treatment optimization [6]. Most of the patients who need chemotherapy in this setting will be offered a regimen that contains anthracyclines and taxanes [7,8]. Although these two agents are considered fundamental in breast cancer treatment, they are beneficial only in some patients and are associated with high toxicity [9,10].…”

Section: Introductionmentioning

confidence: 99%

GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

et al. 2020

View full text Add to dashboard Cite

Background: Breast cancer treatment is tailored to the specific cancer subtype. Often, systemic treatment is given prior to surgery. Chemotherapy induces significant endoplasmic reticulum (ER) stress-mediated cell death and upregulation of 78-kDa glucose-regulated protein (GRP78). We hypothesized that chemotherapy induces ER stress not only in the tumor tissue but also in immune cells, which may affect the response to anti-cancer treatment. Methods: We determined the surface expression of GRP78 on 15 different peripheral blood mononuclear cell (PBMC) subpopulations in 20 breast cancer patients at three time points of the neoadjuvant treatment, i.e., at baseline, after anthracycline treatment, and after taxanes treatment. For this purpose, we performed flow cytometric analyses and analyzed the data using ANOVA and the Tukey test. Serum cytokine levels were also evaluated, and their levels were correlated with response to treatment using the t-test after log transformation and Mann-Whitney U Wilcoxon W test. Results: A significant increase in GRP78 expression in PBMCs was documented during the taxane phase, only in patients who achieved pathological complete response (pCR). GRP78-positive clones correlated with increased serum levels of interferon gamma (IFNγ). Conclusions: The presence of GRP78-positive clones in certain PBMC subpopulations in pCR patients suggests a dynamic interaction between ER stress and immune responsiveness. The correlation of GRP78-positive clones with increased levels of IFNγ supports the idea that GRP78 expression in PBMCs might serve as a new predictive marker to identify the possible benefits of taxanes in the neoadjuvant setting.

show abstract

Neoadjuvant chemotherapy in patients with locally advanced breast cancer

Cited by 3 publications

References 12 publications

Evaluation of neo adjuvant chemotherapy response in patients with locally advanced breast cancer

Evaluation of neo adjuvant chemotherapy response in patients with locally advanced breast cancer

Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer

GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Contact Info

Product

Resources

About